Said in CommitteeBeta

Exactly as spoken.

Insurance and Commerce Committee

February 24, 2017 ·Committee Room 149 ·53:57
Video Transcript

Bills discussed (12)

Bill Title Sponsor Status
HB1585 · 4 mentions in chapter, transcript
Matched: “HB1585 Capp TO CREATE A PROCEDURE FOR THE DISPOSAL OF PERSONAL INF…”
Pre-2017 bill
HB1592 · 4 mentions in chapter, transcript
Matched: “HB1592 Leding TO PROVIDE PARITY IN HEALTH BENEFIT PLAN COVERAGE BE…”
Pre-2017 bill
HB1527 · 3 mentions in chapter, transcript
Matched: “HB1527 Rushing CONCERNING CONTINUING EDUCATION REQUIREMENTS FOR RE…”
Pre-2017 bill
HB1145 · 1 mention in chapter
Matched: “HB1145 C. Douglas TO RESTRICT A JOINT TENANT'S ABILITY TO SEVER A…”
Pre-2017 bill
HB1166 · 1 mention in chapter
Matched: “HB1166 Rushing TO CLARIFY THE OBLIGATIONS OF RESIDENTIAL LANDLORDS…”
Pre-2017 bill
HB1271 · 1 mention in chapter
Matched: “HB1271 Hammer TO CREATE THE ARKANSAS HEALTH INSURANCE INNOVATION A…”
Pre-2017 bill
HB1377 · 1 mention in chapter
Matched: “HB1377 Lemons CONCERNING A WARRANTY EXPRESS DEFECTIVE AGAINST MANU…”
Pre-2017 bill
HB1448 · 1 mention in chapter
Matched: “HB1448 Gray TO INCLUDE FINANCIAL INSTITUTIONS INSURED BY THE NATIO…”
Pre-2017 bill
HB1594 · 1 mention in chapter
Matched: “HB1594 Sabin TO REVISE THE DEFINITION OF "PAID SOLICITOR" AS IT RE…”
Pre-2017 bill
HB1604 · 1 mention in chapter
Matched: “HB1604 Jett TO PROVIDE FOR THE EXAMINATION AND REGULATION OF CERTA…”
Pre-2017 bill
HB1667 · 1 mention in chapter
Matched: “HB1667 Beck TO AMEND THE LAW CONCERNING A PROPERTY OWNER'S BILL OF…”
Pre-2017 bill
SB291 · 1 mention in chapter
Matched: “SB291 Standridge TO REPEAL THE REQUIREMENT FOR THE USE OF CERTAIN…”
Pre-2017 bill

Official video page ↗

Transcript

Transcript available Whisper ✓ SliQ live captions: not yet available Download .txt
Machine transcript

May contain errors. Verify important quotations against the official video.

About transcript accuracy
Source
Whisper
Model
ggml-large-v3-turbo.bin RTX5060
Processing date
October 13, 2026
order. Ladies and gentlemen, welcome to the legislature. Today is going to be one of those days for the new folks that is going to be quite taxing. It's going to start here this morning and then when we get into the general session it's going to continue. There's going to be a lot of very difficult decisions that we're each going to have to make and this is what the people send us for to Little Rock to do, so everybody get your coffee, and we're going to go ahead and get started. We've got a full agenda here today. We're going to have two options. We're going to be able to get through this agenda in an hour, or we're going to come back 15 minutes after adjournment and do it then, so it's going to be up to us to decide how that happens. So the first bill on our agenda is HB 1527. Representative Rushing, you're recognized to present HB 1527. I'll let everybody know we've got a lot of bills, and some of them are controversial, and we're going to get through a set number of these today, even if we need to come back.
▶ Play
Representative Rushing, you're recognized. Thank you, Mr. Chair. I think this one will be pretty easy and not as controversial. We brought 1527 to the table last week. It was dealing with residential, well, not residential, but all real estate education hours. We have gone back with the commission and the Realtors Association and sat down and made an amendment. We took into consideration Representative Ferguson's idea. We are still saying to leave in statute the six and seven hours, but we are also adding in that the commission has the right to go back in after September 1st of 2019 and ask for additional hours through the rules and regs process. So, Representative Rushing, then, to your knowledge, is
▶ Play
there no non-opposition to this one, or are we aligned now? We are all aligned, and
▶ Play
there's no non-opposition. Members, any questions? Seeing none, is
▶ Play
there anyone in the audience that would like to speak against the bill, for the bill? Representative Rushing, are you closed for the bill? I'm closed for my bill. I move, do pass recommendation on House Bill 1527. Is there any discussion? Seeing none, all in favor? Aye. Any opposed? Congratulations, Representative Rush, and you've passed your bill. Representative Kapp, you're recognized to present House Bill 1585. Representative Kapp, you're recognized. Thank
▶ Play
you, Mr. Chair. May I invite Michael Hall of Youth Store It Incorporated and member of the Arkansas Self-Storage Association?
▶ Play
Michael, if you would come to the end of the table and introduce yourself and the organization
▶ Play
you're with for the record, please. You're both recognized.
▶ Play
My name is Michael Hall. I'm with the Arkansas Self-Storage Association. All right. Thank you. A constituent brought this issue to me in regards to House Bill 1585. This bill creates a procedure to dispose and protect others' personal information that are possibly contained in leased self-storage space. This bill is designed to authorize self-storage operators to inspect a client's unit when, the unit has been in default for more than 45 days, and two, the self-storage operators suspect the client may have personal information in the unit. Currently, storage operators are permitted to sell the contents of leased spaces where the tenant is in default for 45 days. There's a public notice auction process that has to take place, and that includes notification by mail. They have to publication in a newspaper of general circulation, and they have to contact the circuit clerk to make sure that there's not any liens or security interest on the property. Now, this bill adds additional methods of disposal of information if it's information that's other than the tenant. And we're talking about patient records of a doctor or a clinic, client records of a lawyer or from a law firm. If upon inspection, an operator determines that contents of the unit contain such information, the operator is required to destroy the information so that it does not pass into any other person's possession. Then the operator can regain possession of the unit and be able to rent it out in a more speedy fashion. This bill does not require an obligation for owners to inspect the contents, only when the owner has reasonable belief that the contents have personal information relating to the client or customer's actual property. They will have the opportunity to destroy the property and rent it out within a 45-day period. And I'd like to turn it over to Mr. Hall to describe the need for this in the industry. Could I
▶ Play
ask you to indulge me, Representative Kapp? Sure. Just see if the members have any questions first. I'm not seeing any hands. Okay, then what I'm going to do is I'm going to let Michael go ahead so that we'll do that and then see if there's questions afterwards, given that there is someone with a question. Are you okay waiting, Representative Eves, until after
▶ Play
he gets to it? Okay, go ahead, Michael. You're recognized. Well, currently, under the statute, we don't have any requirements for the disposal of any property that we come across that has personal information. Um, we, we, we do that currently at my facility, but we just felt it was a good idea to go back and require, to put it in the law to give us a, a requirement for the operator to have to dispose of it properly. Representative Eves, you're recognized for a question. Thank you, Mr. Chair.
▶ Play
I just want to, um, make sure I understand this right and get some clarification, um, representative. So if the storage owner chooses not to inspect, I want to make sure they're not going to be liable.
▶ Play
Is that correct? They're not under obligation to suspect or inspect the property. What the statute says is if they are under reasonable belief, they may, not shall, have an opportunity to look at that property to determine if there is personal information that needs to be taken care of and disposed of. I mean, if you have a storage building that has, it's full of banker's boxes, and it's clear and evident that there's property in there that's most likely not the client's, you know, customer information that they are storing on behalf of other people, then the owner would have the opportunity to look at that and dispose of it instead of having to wait through the process that they do now. because you don't want to sell that information. The people, it's not the client's or the customer's fault that the tenant who's renting the storage building is in default and then all this personal information is stored in there for a period of time. It may end up in the hands of someone else. So what this bill does is it helps the people that are owning these storage buildings and renting them out, it helps them be able to get the property rented back out in a speedy manner and it protects the person's property that are contained within it.
▶ Play
Seeing no more questions, is there anyone that would like to speak against the bill? I'm sorry, Representative Friar, did you have a
▶ Play
question? So I think I would have heard what you say, well, you're doing this now. You're just wanting to codify a law that you want to make a law that makes it okay for you
▶ Play
to do it. You're disposing of the property. Currently, if somebody buys the unit and then they find something like that and they don't want it, they'll leave it, and then I come across it. I try to find the owner. When I don't find the owner, I hold on to it, and then I call a shredder. I shred it up. But then I realize that there's no requirement to destroy and shred it, and so that's why we felt it was a good idea to present this bill because currently we have no avenue to destroy the stuff. All right.
▶ Play
So let me ask if you agree with my summary of what the bill is. In the current situation, there are question marks about when you get my private information, what you're supposed to do with it, and whether or not I can sue you. So what this does is it makes it clear what your responsibility is so you'll know whether or not I can sue you for having my personal information. Is that correct? I believe, yes, sir. Pretty good. Are there any more questions from the committee? Seeing none, is there anyone to like to speak against the bill, for the bill? Representative Kapp, would you like to close for your bill? I'm closed. Representative Kapp indicates she's closed. I move do pass on House Bill 1585. Is there any discussion? Seeing none, all in favor? Aye. Any opposed? Congratulations, Representative Kapp, you've passed your bill. Representative Letting, you're recognized to present House Bill 1592. Thank you, Mr. Chair, and I have some women who are going to join me
▶ Play
here at the end of the table. Would you like them to introduce themselves before
▶ Play
I begin? Yes, sir, if everyone introduces themselves and who they're with, then you're all recognized to present House Bill 1592.
▶ Play
Speaker 48 9:29
Good morning, my name is Lauren Marquette. I'm the Executive Director of Susan G. Komen Ozark
▶ Play
Speaker 47 9:36
Affiliate. I'm Sherry McBride. I'm the Executive Director of the Arkansas Affiliate of Susan G. Komen. And
▶ Play
my name is Vicki Cowling, and I'm the Missions Director for the Komen Ozark Affiliate. Okay. Thank you,
▶ Play
Mr. Chair, Madam Vice Chair, members of the committee. We will be very brief. Over the last 10 years, the rise in use of oral chemotherapy has increased significantly as doctors and patients have come to recognize the benefits of that treatment. As the name suggests, oral chemotherapy is just a treatment that you do take orally. It can come in pill or liquid form. It allows a patient greater control over when and where she takes her medication. It can allow her greater exposure, more prolonged exposure to the treatment, as opposed to only occasionally being able to go to a clinic to receive IV treatment. It also reduces the need on healthcare resources and ambulatory services, because it allows a patient to be able to take her treatment by herself at home, as opposed to having to travel to a clinic, which could be a great distance away. In short, it reduces the demand on the health care system, and it can also provide a greater quality of life for patients who are fighting cancer. One of the biggest obstacles to this treatment is currently the cost. Oral care, their chemotherapeutic treatments can often just be too expensive for most patients. And when a patient receives a prescription and gets that prescription filled, She has to pay at the time that the prescription is filled, and co-pays can often be several thousands of dollars. Our own Senator Greg Standridge, who is the Senate sponsor on this bill, is currently undergoing multiple forms of chemotherapy for his cancer. One of them is oral chemotherapy, and he can tell you all about the costs involved. Forty-two states have ensured better access to oral chemotherapy by ensuring parity. Obviously, we would not be here this morning if Arkansas were not among the remaining eight. I will note that in Arkansas, you are actually less likely to contract cancer than most states in the country, which is the good news. The bad news is that if you contract cancer in Arkansas, you are more likely to die of that disease than in other states. We have about 390 to 440 cases of cancer per 100,000 Arkansans a year. And unfortunately, about 290 to 300 of those Arkansans per 100 pass away from their disease. So House Bill 1592 would put this treatment within greater reach of more Arkansans and, we think, be able to save lives. So
▶ Play
what I want to understand is there's two ways of doing the cancer treatment. One of them is oral, one of them is intravenous. One of them the insurance companies will pay for, the other one they're saying that they won't pay for. Is that correct? That's correct in some cases, yes. Okay, and what is the reason that they're going to pay for intravenous but not oral? Some insurance companies consider the oral chemotherapy under the pharmaceutical benefit. What is the difference in the cost between the two options? Do we know that?
▶ Play
I've had people say that co-pay for the oral chemotherapy can be as high as about $10,000 or more. That's just about a quarter of the state's median income. But if
▶ Play
the oral is $10,000 or more and the intravenous is, what is that? Is that like $1,000 or is it also $10,000? The women
▶ Play
with me might be able to better answer that question, but there's better insurance coverage for that treatment.
▶ Play
Would you like to respond? It's covered under the medical plan, and it's just a typical copay. So, and again,
▶ Play
I think Representative Payne wants a question as well, but I'm trying to get an answer to this. I understand who pays and how pays, so that's not my question. My question is the cost. In other words, a Cadillac costs one price, and a Toyota Celica costs another price. That's what I'm interested in. Can I get the two prices for the two treatments? Does anyone have that? We don't have that at this time. Representative Payton,
▶ Play
you're recognized for a question. Thank you, Mr. Chair. I guess my concern is with insurance rates already going up and making it so hard for people to afford the coverage, I mean, is this not going to raise the rates? And if fewer people end up covered because they can't afford
▶ Play
Speaker 47 13:49
the rate, then it's very counterproductive. In the 42 states where this has passed, there had been no significant increase in the premiums because of this. It's actually a cheaper way to give the oral drugs. You don't have to administer it in a clinic. I have a
▶ Play
follow-up. Representative Payton, you're recognized for a follow-up. I don't know what the list
▶ Play
of 42 states is, but reading the news reports for the last two or three years, I can't imagine that you have 42 states that have not seen a significant increase in insurance coverage
▶ Play
cost. The list of states that have not done this is Montana, Idaho, Michigan, Arkansas, Tennessee, North Carolina, South Carolina, and Alabama.
▶ Play
Well, then Arizona would be one of the 42, and I know their rates have skyrocketed. But do you know for
▶ Play
sure that that's directly related to this particular issue? Do you know for sure it's not? Representative Savillo,
▶ Play
you're recognized for a question. Thank you, Mr. Chair. As a cancer survivor, I did take an oral, it was called thalidomide. And I took it for 13 months, it was about a $2,000 drug. Obviously, it was successful in my treatment because I'm still
▶ Play
here. So, Representative Letting, I'm really struggling with not being able to make a judgment between the burden that we're going to put on insurance payers, how much money are we going to ask them to spend in addition to what they could spend if they did it the other way. And in the absence of that, I have a lot of concern. So I don't know if we can get an answer to that while we're sitting here or if we could come back another day with that, but that's a real concern to me. Can you help me with that? I do know the American Cancer Society is here to testify in
▶ Play
support of this bill and may be able to provide some additional information. Again, this same language is passed in a number of other states. They have not seen a significant increase in their rates due to this particular treatment. And this would put this treatment in the hands of more Arkansans. I understand that. We have some of the most regulated
▶ Play
markets in the country in our state. And we pass unfunded mandates, and then people have rates go up. And that's my concern, and I just don't know how much we're adding to the bill. So I would also be
▶ Play
concerned about the person who has cancer and could definitely benefit from this particular treatment. Yes, sir, that is true. Representative Farrar,
▶ Play
you're right, can ask for a question. Thank
▶ Play
you, Mr. Chair. I've actually had a Hodgkin's lymphoma, and they didn't have oral when I had it. I would have gave my arm to have oral than having chemo. So I see the concerns, what they're having, and there's not a – what is the difference in cost? I think we're going to do it again. What's the difference in cost on these two drugs? Again, if it's oral, it's 100% better than having a port put in and having four drugs stuck in you for three hours, believe me. So tell me the cost differences, and what's the effect on the insurance companies? I know chemo is expensive, even though this put in the liquid form is $50,000 of treatment, I think is what it was.
▶ Play
What would be the savings if you go to an oral? We will get an answer on the cost between the two different treatments. But again, I will say that the insurance
▶ Play
companies in the states where this has passed have seen no increase in their rates. Representative Jett you recognize your question. Thank you Mr. Chairman. As my wife's been diagnosed with terminal stage 4 breast cancer and I've seen people who've actually walked away from the chemo part of the drug because they could not take it anymore and decided to die. I would I would like to hear your explanation of how we can justify the cost between people taking a drug or taking it orally
▶ Play
for quality of life. The oral chemotherapy does provide a greater quality of life. It allows the patient to take the drug as she can at home in the comfort of her own home. And again, it provides greater exposure to the drug because she can take it more regularly. doesn't have to worry about traveling to a clinic, perhaps great distances or even out of state. So I really can't justify why this particular treatment would be
▶ Play
so further out of reach
▶ Play
for cancer patients in Arkansas. Representative Ferguson, you're recognized for a question. I think I understood you that the real discrepancy is between insurance companies have a pharmacy benefit and they have a medical benefit. And the IV drug is given as a medical benefit with the medical deductible. And the pharmacy oral medication is a separate insurance benefit that's a pharmacy benefit with a copay. Correct. Is that correct? Correct. I guess the other thing I would ask is cancer is not one disease. It's hundreds of diseases with hundreds of medications. So to get a cost answer, you would probably have to look at each specific situation. Would that be right? I mean, you have to look at the IV versus the oral in literally hundreds of cases. Right. But I guess what I mean, you say states who have done that, there's been no increase in the cost of the insurance premium as a result of allowing orals? That's correct.
▶ Play
Speaker 48 19:11
Okay. Thank you. Yeah, and I also would like to add that the new cutting-edge research is more of oral chemotherapy. So that's why we're seeing this now, and that's why we're here talking about it today. And that's why it's such a high cost, and it's not covered under the medical as well. So a lot of the new cutting-edge research is moving towards that. Could
▶ Play
you answer for me, which people would this apply to? Will this apply to companies, the Walmarts and all of them? or would it just apply to the government programs, Medicaid, and those programs?
▶ Play
Speaker 48 19:47
So we're also, we actually in a few weeks are going into Washington, D.C. to talk to our Arkansas delegation about oral parity on a federal level as well. So we are making sure that it's covered across the spectrum and that we're not talking about just one insurance here as
▶ Play
well. So if I play back what I heard is the answer, What we're really doing is this is going to apply to the Arkansas Medicaid program, Arkansas taxpayers, but not the private businesses and those insurances which are covered by the federal rules. Is that correct? Currently, we are
▶ Play
Speaker 48 20:20
still working on a federal level to make sure that they also are able to pass oral parity as well. The fight against
▶ Play
cancer is a multi-front war, and we're just fighting every battle we can. I understand that, sir.
▶ Play
I'm just trying to figure out what we're doing here today. I only get a little tiny spot. I'm just the peon. So this is going to apply to our Medicaid programs, and whatever the gap is in the cost, which was undetermined at this time, is what we're going to pass on to the taxpayers? Is that essentially the
▶ Play
scope of this debate? Yeah. All insurance.
▶ Play
Well, what is ERISA, please? Can someone tell me what is covered by ERISA then? Okay, so the federal self
▶ Play
Speaker 88 21:23
insurance. Representative Hodges, you're recognized for a question. Thank you,
▶ Play
Mr. Chair. Maybe following on your question, my question was going to be Representative Letting. If the health insurers have been aware of this bill and if any of them are maybe here to testify against the bill, because it might raise the cost or raise the price to their consumers. It would seem that if they think that's going to happen, they
▶ Play
might be here to speak to that. Blue Cross Blue Shield, I believe, is here to speak this morning. They said they're not opposed to the concept, but they do have a concern that they'll share with the committee
▶ Play
later. Representative Farrar, you recognize for a question? Are there any other questions from the committee? Representative Payne, you're recognized
▶ Play
for a question. Well, I may have missed it or forgot it, but have you spoken about the effectiveness, whether it's more or less effective than the IV as far as the success of treating cancer? It can depend on the cancer type, as Dr. Ferguson
▶ Play
referenced, there are going to be hundreds of types of cancers at different kinds of treatments. But there's no notable difference in the success or rate of the drug. It's just as effective as other forms. So with no known advantage, it's just a cost? No, again, there are a number of advantages in that it provides greater flexibility to the patient. She doesn't necessarily have to travel to a clinic, which if you're living in rural Arkansas, 54 of our 75 counties are rural. She might have to travel a great distance and spend time in a clinic, so she's having to take time off work. This allows her to take the treatment at home. They can provide greater exposure to the treatment, because she can take it more regularly without having to travel to a clinic. So she's getting a more sustained exposure to the drug to fight the cancer. And it cuts down on the resources of the healthcare system, because she's not having to go to a clinic and see staff. She can again just take it in the comfort and privacy of her own home. Can I have a follow up? Representative Payton, you're recognized for the follow up.
▶ Play
Okay, I think you answered my question very well there. What about tolerance? I mean, Representative Jett spoke about, you know, a lot of people just quit taking chemo because it makes them too sick. Is there any difference in the tolerance on the oral versus the intravenous?
▶ Play
Speaker 48 23:36
So we can speak from our experience of the women that come in our office and that we deal with, and we have heard a resounding that they particularly have had less side effects, and it's been able to, the woman we're here representing today who has three children and the youngest is seven, And she's been able to work and take care of her kids still, whereas the first time she went through the IV medication, she was really sick and wasn't able to do so. So the quality of life is different for her, absolutely. But also I will add, too, is that, you know, we were talking about cancer being so many different diseases, and we know that breast cancer alone is so many different diseases, and that especially for our most aggressive type of breast cancer, that's where the new cutting-edge research is coming in, which is the oral chemo, and so they know that, you know, they have a better chance living a longer life if they have access to the best treatment, which is possibly that oral chemotherapy. Representative Vaughn, you're recognized
▶ Play
for a question. Thank you, Mr. Chair. I'm sorry I was late. I was running a bill on another committee, so I might have missed this. I love the idea. That's why I co-sponsored it. I think it's a great idea. One thing that I do want to make sure about, though, is the physical impact that we're going to how much is this going to cost the state, things like that.
▶ Play
Can you give me any of those, please? I'm sorry, I was
▶ Play
late. We really don't think there should be a cost to the state. Okay. Representative Sevilla, you're recognized for a question. May I just make a comment concerning the issue? I was on three drugs. Two of them were injections that I received four times a week. The oral drug I took was every day. The injections continued for six months, and I have to tell you, with the oral drug, the three drugs at the same time, it did knock my socks off in the early stages. Thereafter, after six months, they reduced the injections and I stayed on for the next seven months, which is a total of seven months with the oral drug. And by the end of that time, I had really had regained almost all my ability. So I support what you're saying, and that there is a, in essence, there's a blend in this situation of injectable and then also oral. Mike, let me ask the question
▶ Play
this way. DHS, the Healthcare Task Force, has been working on a plan to bend the cost curve on our healthcare plans. and there's a lot of work that's being built into those things. So if on the outside of that we're adding massive new costs, and I'm going to say massive new costs because I don't know how much we're adding, separate from that effort, I'm concerned about what that impact is, and I think I'm worried that it's significant, and I'm looking for somebody to help me with that somewhere on this. So I can be for it because I don't like cancer either. We've only got so much money or the programs will go bankrupt. So that's what I'm struggling with. Can someone help me? Well, if we don't know the cost, then I
▶ Play
wouldn't necessarily apply an adjective either way, but that's just me. Then please give me a number, sir, so I don't have an adjective to use. We do have implementing this change as cost insurers less than 50 cents per month for most plans. And, again, as we've already said, greater access to oral chemotherapy can reduce the demand on health care resources because, again, patients are able to take the treatment by themselves at home without having to travel to a clinic. So not only are you lessening demands on the health care system,
▶ Play
but you're also using less ambulatory services. So let's do the math together. Then 50 cents a month times 1 million people on Medicaid is $6 per person times 1 million. So that's $6 million per year in the Medicaid program. Is that a reasonable estimate?
▶ Play
You're a little bit quicker with the math than I
▶ Play
am. Representative Eves, you're recognized for a
▶ Play
question. Yes, Chairman Collins, in your math, are you considering the fact that these people might take the oral medication rather than the injections, and then not have to incur those costs during that process? And we're talking about people's lives here.
▶ Play
I heard him say 50 cents of an increase compared to the existing premium. So this change, the math that I ran, assumed it was an increase versus today's rates, which include the other. And I'm worried, sir, as well, that if we don't have any money at the end of the day, we won't be able to take care of people down the road, and that's another concern that's important, too. I would just add that one
▶ Play
of the additional costs to the health care system are non-adherence costs. The patient does not adhere to her regime for any number of reasons, perhaps because she's not able to continue to afford the treatment or she cannot regularly provide or have access to transportation to receive her treatment. And so non-adherence costs cost the U.S. healthcare system an additional $100 billion each year in unavoidable hospitalizations. Representative Fari, I can ask for a question. Representative Lidding, would you say that if
▶ Play
this patient, not her, these patients were on Medicaid, that if they would give the oral drug instead of the chemo drug, interventionally would the cost of non-emergent transportation go down? I would say so, yes.
▶ Play
Thank you. Representative Vaught, you're recognized for a question. Thank you, Mr.
▶ Play
Chair. Is there someone here from DHS or Blue Cross Blue Shield who can answer the questions about the money, the fiscal end? I do believe there is somebody
▶ Play
from Blue Cross Blue Shield. I'm not sure about DHS. Could they come to
▶ Play
the table and answer them? Okay. Any other questions from the committee? Is there anyone that's here to speak against the bill? Max, you're recognized to speak against the bill. Please share your name and who you're with. Thank you, Mr.
▶ Play
Speaker 117 29:46
Chairman. I'm Max Greenwood. I'm with Arkansas Blue Cross and Blue Shield. We just, I'm sorry. Max, is your machine on
▶ Play
Speaker 80 29:56
as you push the button? It's on. I'm
▶ Play
Speaker 117 29:59
sorry. When this bill was filed, we have been trying to reach out to the sponsors, and we just met with them this morning. We have some concerns about the language in the bill. We believe it's very, very broad. And specifically with regard to Section 2A, we believe that that language would basically shift costs to private policyholders. and it's overly broad in the sense that it would preclude carriers from designing plans that would give consumers the ability to pick and choose what type of deductibles and coinsurance they would have. As far as putting a cost on this one element, we're not able to do that. We don't treat cancer drugs any differently than we treat any other drug. As you've already discussed, if you have knee surgery and you have an intravenous drug, that all goes toward the medical portion of your plan. If you're taking oral chemotherapy, that goes to your drug prescription plan. So in order to carve out cancer drugs, it's not doable from an actuarial standpoint. We do believe that this bill will add cost, even though the intention is not. And one of the things we did ask the sponsor this morning was what specifically is occurring with regard to Arkansas Blue Cross plans that you all are trying to fix. and we are still not clear as to what the issue is with regard to fully insured policies. So, Max, let me ask you
▶ Play
this question. Do you think it's possible to work out an amendment to this that could make it so that we could have some of the benefits without as much of the risk to the costs with the sponsor? Do you think that's possible?
▶ Play
Speaker 117 32:13
What we're doing right now is we're waiting on language from the regional director for our attorneys to look at and our medical director to look at as well. I think the concern is that it is so broad that it would inadvertently end up costing the policyholders more in the long run. With regard to Arkansas Works and DHS, I can't speak for them. Representative Lundstrom, you're going to ask for a question. If Blue Cross
▶ Play
and Blue Shield were to get
▶ Play
involved, they're a pretty big carrier in our state. Do you think they could negotiate cost down on the oral medication? We, you know. Even though I know it's a pharmacy deal, but once y'all get involved, y'all
▶ Play
Speaker 117 33:00
swing a pretty good bat. But we already use a PBM to negotiate. I mean, you know, we negotiate the best we can for our members. this bill isn't going to impact us being able to negotiate better or worse. If the cost of drugs goes up, for example, this bill would lock everyone in to that amount. So, for example, let's just say, you know, at the beginning of the year, your intravenous drug is $200. What if that drug goes up to $2,000? You know, you're going to be locked in, and I understand what they're trying to do. What we're trying to do is to make sure that the language is not overly broad, and impact the cost of policies. Representative Ferguson, you recognize for a question?
▶ Play
Yeah, and I guess I've known this has been an issue with oncologists for a long time. And I guess I've really never understood the insurance side of the issue because I understand a lot of oncologists choose to have the patient come in every day and give the IV chemo because at that point the patient's already met their deductible. But it seems to me that that would be more expensive for insurance because you're going to have a facility fee. You're going to have staff, all of those issues of going to the office instead of just letting the patient stay at home and take an oral medication. I don't understand the cost-benefit analysis for the insurance company, I guess, because it seems counterproductive to have oncologists give the IV drug instead of the oral. Can you explain that? I guess I don't understand why that would be a cost-benefit for insurance to have that facility fee and having the patient come in and get an IV every day or two or three times a week instead of
▶ Play
Speaker 117 35:07
just taking oral chemo. I can't address how doctors administer care to their patients. I mean, all I know is that there's the medical side of the benefits, and there's the drug side of the benefits. We don't get involved in how doctors treat their patients. Representative Ferguson, you recognize the
▶ Play
follow-up. I don't think you're answering my question.
▶ Play
I'm not understanding. I'm sorry. I mean, no, absolutely. I'm telling you that oncologists intentionally choose the IV over the oral because the insurance will pay for it. And if they give them the oral, which may be as effective, I'm not saying they would give a less effective drug to give IV, but when they're given the choice and the patient has no out-of-pocket cost compared to having to go to a pharmacy and get a prescription filled, And I just, I don't see how that, I guess I need you to explain to me how that is not anything to do with the doctor's decision, but how is that cheaper for an insurance company to pay for those expensive IV drugs and the facility fee and all of that compared to letting
▶ Play
Speaker 117 36:19
them take the oral med? I don't think it would be, Representative Ferguson, and I don't think that that's what the issue is here. I mean, in our opinion, the language of the bill is much broader than just dealing with that narrow issue that you just phrased. And that's what we're trying to work with the sponsor and the representatives from the Komen Foundation on. You know, we don't believe that it is cheaper. And obviously, you know, we want the member to have the best treatment in the most appropriate setting. But they're in two different buckets with regard to cost. And there's no way to move them to the same bucket without carving out cancer drugs. And you can't, from a policy and a coverage standpoint, there's no way to merge those two buckets. And that's what we're trying to figure out, how to best do that without impact all the other drugs and medical side treatment that this bill, we think, you know, it goes too far.
▶ Play
Well, and I mean, I understand there are two buckets, like Charlie likes to talk about our buckets. But eventually it's all coming out of the same bigger pot, right? I mean, would it help to transition to this so that you can work with the PBMs? I mean, I'm just thinking, you know, it's so much more convenient for the patient to be able to stay at home where they're comfortable and take oral chemo. And I don't want it to cost more. I guess, is it that the co-pay is so exorbitant on the pharmaceutical side that the insurance company saves money because they ultimately don't have to pay for the oral med?
▶ Play
Speaker 117 38:09
All the co-pays are different depending on the plan. Right, yeah, I know. What I don't know is the exorbitant co-pays that are being cited, what types of plans are those aligned with? You know, if they're self-insured plans, this bill is not going to address that. If they're fully insured plans, you know, there is an array of plans for people to choose from based on what best fits their need. I don't know the plan that we're talking about. I don't know that it's ours.
▶ Play
I mean, yeah, I understand. Representative Ferguson, can I ask this question, Max? It sounds like, from your vantage point, I'm just listening, that there is a workable solution that can enable us to move forward on this. So my question is, it sounds like you're in the mix with the sponsor of the bill. Is that your sense that we can either A, give you an opportunity, confirm that you can live with it as written? B, work with them to see if you can put the elements in there that give you comfortable. It won't knock the costs out of the House. Is that reasonable to believe in your eyes that that is possible over the next handful
▶ Play
Speaker 117 39:17
of days? What's reasonable, Mr. Chairman, is that we cannot live with the bill as it is written right now. And we are waiting to see if there is language we can live with. And we have not yet seen that language. And like I said, we just were able to meet with the sponsor this morning. So we're hopeful. Okay,
▶ Play
thank you very much. I've got, you know, it looks like a half a dozen more questions here. And if we're going to ask questions that don't try to work out the language, we can go through them. Because if the answer is we're going to try and work out the language at the committee, what I would recommend instead is that we have the sponsor and the Blue Cross folks sit down and see if they can work out the language. which if Representative Letting, if you're willing to do that, that may be a solution that works. If you're not, then we can obviously run the bill. That's your prerogative, so. Just for
▶ Play
request. I guess I would like a fiscal impact from Medicaid as well, if we're going to let them work on it.
▶ Play
I support that recommendation. Representative Letting, what is your point of view on this?
▶ Play
I would say that the bill has been filed for 72 hours, and this exact same language is passed in a number of other states where Blue Cross Blue Shield has challenged it. So I take a little bit of issue with the fact that they haven't been able to come up with a recommendation for this specific section. In addressing to some of the problems we've seen in Arkansas, Eric Noble, the CEO of Noble Impact earlier this week, contacted me with his personal story. He was diagnosed with brain cancer in September of last year, and his doctor recommended an oral chemotherapy treatment, and he had to fill out a waiver with Blue Cross Blue Shield, and the paperwork took about a week, delaying his doctor's treatment plan for
▶ Play
him. So Representative Letting, Blue Cross Blue Shield is owned by multiple entities. The biggest one owns California and several others. The Arkansas Blue Cross Blue Shield is independent, so what happened in other states wouldn't apply to them here. But I hear what you're saying. I take that as no. I still think they probably would have heard about this legislation since it's been run in a number of other states, and 42 other states have passed. Sir, working things out, it's a painful process, trust me, I can tell you. It's painful, painful, but that's one of the things that can get us places. Representative Jett, you're recognized for a question for Max. Thank you, Mr. Chairman. I think you
▶ Play
actually answered my question, what you're trying to reach for. But I would say this, this bill's been filed since four days ago, I guess, 72 hours. And I'd ask the lady at the end of the table, at what time did you reach out to the sponsor of the bill to actually work out a workable solution? Did you show up yes or no this morning without reaching out to the sponsor of this
▶ Play
Speaker 117 42:00
bill? Representative Jett, we started reaching out to the sponsor Wednesday to try to set up a meeting to discuss the bill. We did not hear back until last night, and the meeting was set for 8 a.m. this morning. Thank you, ma'am. I
▶ Play
appreciate you. Representative Sevilla, you're recognized for a question. A motion at the proper time. Representative Eves, you're recognized for a question.
▶ Play
Thank you. So there's other Blue Cross companies that have apparently been okay with this. I think what was the last state, South Dakota? And what is different about the language that those states are passing that Blue Cross is okay with? I mean, I'm trying to understand why
▶ Play
Speaker 117 42:43
we're the only ones as Blue Cross having this problem. Representative Eves, I don't know what occurred in the other states. I will tell you that all the blue plans are independent plans. Every state has its own insurance policy and insurance department and regulation. We saw the language when the bill was filed. This bill has never been discussed before in Arkansas, to my knowledge. And as I said, when we saw the bill and we had our folks look at the bill and the concerns were brought to us, as we began reaching out to the sponsor to try to sit down and have a discussion about it. I don't know what the issue in the other states were. I know that our attorneys plan to reach out to other plans to find out.
▶ Play
Representative, you recognize for a follow-up, but just a point of clarification. I think Representative Letting said that Blue Cross and all the other states was against it as well. That's what I heard him say, if I
▶ Play
recall correctly. Okay. I didn't hear him say that he may have. Is it possible that Arkansas's Blue Cross could reach out to the other state's Blue Cross companies and find out how they had or what kind of workable solution they came up with? Yes, sir. Representative Warren, you're recognized for a question.
▶ Play
Thank you, Mr. Chairman. My question is the intravenous versus the oral. Is it the same medication? And if so, how do you authorize payment for one and not the other? I
▶ Play
Speaker 117 44:20
don't know that we authorize payment for one and not the other,
▶ Play
Representative. It's being done in clinics intravenously. So if it's the same medicine, why is it not paid for orally?
▶ Play
Speaker 117 44:33
I was not told that it wasn't being paid for orally. It's my understanding that it's not that it's not being paid for, it's just that the benefits for something applied intravenously may be different than the benefits for something that is taken orally. Okay, I guess my point
▶ Play
is it sounds like if it's done within a hospital or a clinic, it's pretty much covered with a- Medical benefit. Medical, if it's medical benefit, basically where it's being done. If it's done in a clinic or a hospital, it's pretty much covered with a low
▶ Play
Speaker 117 45:24
deductible. With whatever deductible your medical benefit has. But if you choose to
▶ Play
have it done orally, away from the clinic or the hospital, you're paying the largest percentage of it? It
▶ Play
Speaker 117 45:36
would be under your prescription drug benefit, which may or may not be.
▶ Play
But it's the same treatment. It's the same treatment. Yes, sir. Okay. Is there anybody from DHS here? There's nobody from DHS here? Representative Richman, you're recognized
▶ Play
for a question. Thank you, Mr. Chair. It was indicated to me that Representative Letting reached out to Blue Cross Blue Shield back in December to say that there's a possibility that he was going to run this bill.
▶ Play
Speaker 117 46:14
Are you aware of that? What I'm aware of, Representative Richmond, is that there was some national language that Representative Letting did send to the company. But we never heard back as to whether or not there was going to be an actual bill filed. How that language compares, I don't know. All right, thank you.
▶ Play
Representative Lowry, you're recognized for a question? Yes. I actually have an inquiry of the Chair, if that's permissible. Yes. We've already heard Representative Ferguson request a fiscal
▶ Play
impact. is that something that we should be waiting on, the committee should wait on? Because I would think if it's our job to more carefully vet these bills than can be done sometimes on the House floor, that we should be the ones to be able to see the fiscal impact before this bill moves forward. I'm going to
▶ Play
take that as a motion, Representative Lowry, if you want to make it. Yes, I do make that motion. All in favor of, first of all, is there any discussion on the motion of asking the sponsor to get us a fiscal impact on this. Seeing no discussion on the motion, all in favor say aye. Aye. Any opposed? No. The ayes have it. So, Representative Letting, what we would like you to do, please, is to get a fiscal impact for this bill, and then we will put it at the top of the list when we have that. Will do. Thank you, committee. Thank you. Representative Sabin, are you here? I think you said you want to do this 3-1, so Representative Sabin is not here. The next bill on the list, Representative Jett, you're recognized to present HB 1604. In my understanding is we have an amendment. Everybody can plan to come back 15 minutes after adjournment. Hopefully, we're going to get through 1604 now, and then we're going to come back 15 minutes after adjournment, and we will cover Senate Bill 291 15 minutes after adjournment, and we may have another bill after that as well. Representative Jett, you're recognized to present HB 1604. Thank you, Mr. Chairman. Members, there is
▶ Play
an amendment on this bill. It's my amendment. My bill just clears up some language that the Banking Commission has to put in there, and I appreciate the adoption of the amendment.
▶ Play
Are there any questions on the amendment? Seeing none, is there anyone here to speak against the amendment? For the amendment, I move that the amendment be adopted. Any discussion? All in favor? Aye. Any opposed? Congratulations, the bill is amended. Representative Jett, you are recognized to present HB 1604
▶ Play
as amended. Thank you, Mr. Chairman. Members, this bill simply states that the Banking Commission for the state of Arkansas has authority to regulate and audit Arkansas Capital Corporation. It's agreed upon amendment, I mean, agreed upon bill. The Capital Corporation wants to be regulated and audited by the Banking Commission. The Banking Commission agrees to do that, and the fees between both entities have been worked out and approved. With that, I'd appreciate
▶ Play
a good vote. Are there any questions on House Bill 1604? Seeing none, is there anyone that would like to speak against the bill? For the bill, seeing none, I move that we pass HB 1604 as amended. Is there any discussion? All in favor? Aye. Any opposed? Congratulations, Representative Jett, you passed your bill. What I'm going to do with the indulgence of the committee, Representative Lemons is able to be with us today and And he's got a lot of other challenges in terms of being able to come back. So without objection, I'm going to recognize Representative Lemons, and we're going to remove HB 1377 from the deferred list. Representative Lemons, you're recognized to present HB 1377.
▶ Play
Thank you, Mr. Chairman. I was perfectly willing to come back after session, but I appreciate it. What my bill pertains to is, in layman's terms, if you put a new roof on your house, and you get a warranty from the manufacturer of the shingles. And say it's a five year warranty, a year after you've done this and you move and you sell your house to someone else. You're supposed to, in the warranty, it typically says that you're supposed to tell the new owner that you have to transfer the warranty. If you don't, the warranty is null and void. What we would like to do is to attach the warranty to the structure and not the person that is living in the house like it should be. Be glad to answer any questions you may have.
▶ Play
Are there any questions from the committee? Seeing none, is there anyone here to speak against the bill? For the bill. Representative Payton, what we'll do is we'll wait until we get to the motion and there will be discussion on the motion. Representative Lemons, are you closed for your bill? Yes, sir. All right, I move do pass on HB 1377. Is there any discussion on the motion? Representative Payton, you're recognized. Thank you, Mr. Chair. I'm just wondering if other states have
▶ Play
done this, or are we going out and
▶ Play
sailing on here? I'm unsure what other states have done, to be honest. This is just a need in Cabot. We have got a lot of construction going on, and it has reared its ugly head more than once. And in this development, you're going to see it.
▶ Play
I mean, if I may, I'm in the automobile business. We have warranty coverage, and we have the requirement that if the vehicle changes ownership that they can transfer the warranty, but it doesn't automatically do it. I can see where changing that would affect a lot of warranty companies. And I don't know who these shingle companies are, or if they're in state or out of state whether we have the power to regulate them or not? I mean, this is kind of like uncharted territory in my mind. Maybe somebody else on the committee has some experience here. But if it's an out of state company that produces the shingle and guarantees the shingle, how do we have the authority to force them to
▶ Play
warranty it? If you look at the warranties, what I have seen, there is an extremely fine print like a size five or six font at the bottom that says that this warranty is good for the person that has purchased it. If you transfer the house, title of the house to someone else, you must then request it from the warranty company to transfer it at that time. We're trying to streamline this because most people, they don't read a size
▶ Play
Speaker 154 53:11
4-6 font when they're at the closing. Is there any more
▶ Play
discussion on the motion? If not, all in favor? Aye. Any opposed? Congratulations, Representative Lemon, you've passed your bill. Thank you, Chair. I apologize to all the people that came in for SB 291 that you're going to have to stay until after the session. I apologize. When we get to this point in the session, sometimes there are just too many things to get done, and we're just going to have to wait. I would start it now, but five minutes isn't going to get anywhere near what we need, and I think we'll be better off just having recess until after the session, 15 minutes after session, then we'll take up SB 291. Thanks for everybody. We're in recess. You
▶ Play

Agenda

REGULAR AGENDA

Number Sponsor Subtitle

HB1527 Rushing CONCERNING CONTINUING EDUCATION REQUIREMENTS FOR REAL ESTATE LICENSEES.

0:00 - 3:47 13 segments 4 speakers

HB1585 Capp TO CREATE A PROCEDURE FOR THE DISPOSAL OF PERSONAL INFORMATION CONTAINED IN A LEASED SELF-SERVICE STORAGE SPACE.

3:47 - 9:13 16 segments 6 speakers

HB1592 Leding TO PROVIDE PARITY IN HEALTH BENEFIT PLAN COVERAGE BETWEEN ORALLY ADMINISTERED ANTICANCER MEDICATION AND INTRAVENOUSLY ADMINISTERED ANTICANCER MEDICATION.

9:13 - 48:08 157 segments 20 speakers

HB1594 Sabin TO REVISE THE DEFINITION OF "PAID SOLICITOR" AS IT RELATES TO SOLICITATION OF CONTRIBUTIONS FOR CHARITABLE PURPOSES.

HB1604 Jett TO PROVIDE FOR THE EXAMINATION AND REGULATION OF CERTAIN ECONOMIC DEVELOPMENT FINANCE CORPORATIONS BY THE STATE BANK DEPARTMENT; AND TO DECLARE AN EMERGENCY.

48:08 - 50:32 8 segments 3 speakers

SB291 Standridge TO REPEAL THE REQUIREMENT FOR THE USE OF CERTAIN AFTERMARKET CRASH PARTS IN REPAIR OF A VEHICLE.

HB1448 Gray TO INCLUDE FINANCIAL INSTITUTIONS INSURED BY THE NATIONAL CREDIT UNION M. ADMINISTRATION AS INSTITUTIONS ALLOWED TO SERVE AS DEPOSITORIES OF PUBLIC FUNDS.

HB1667 Beck TO AMEND THE LAW CONCERNING A PROPERTY OWNER'S BILL OF RIGHTS.

DEFERRED

Number Sponsor Subtitle

HB1145 C. Douglas TO RESTRICT A JOINT TENANT'S ABILITY TO SEVER A JOINT TENANCY WITH RIGHT OF SURVIVORSHIP IN REAL PROPERTY; AND TO DECLARE AN EMERGENCY.

HB1166 Rushing TO CLARIFY THE OBLIGATIONS OF RESIDENTIAL LANDLORDS AND RESIDENTIAL TENANTS; AND TO REQUIRE IMPLIED QUALITY STANDARDS FOR TENANTS OF RESIDENTIAL REAL PROPERTY.

HB1271 Hammer TO CREATE THE ARKANSAS HEALTH INSURANCE INNOVATION ACT OF 2017; AND TO DECLARE AN EMERGENCY.

HB1377 Lemons CONCERNING A WARRANTY EXPRESS DEFECTIVE AGAINST MANUFACTURER'S ASPHALT ROOF SHINGLES.

50:32 - 53:59 12 segments 4 speakers

Documents

No documents posted.

Speakers

Representative Charlie Collins Chair Unverified
65 segments
Representative Laurie Rushing Unverified
3 segments
Representative Sarah Capp Unverified
8 segments
Michael Hall Unverified
1 segment
Chair Unverified
9 segments
Representative Les Eaves Unverified
4 segments
Representative Joe Farrer Unverified
4 segments
Representative Greg Leding Unverified
29 segments
Speaker 48
9 segments
Speaker 47
3 segments
Vicki Cowling Unverified
2 segments
Representative John Payton Unverified
9 segments
Representative Joe Jett Unverified
7 segments
Representative Kenneth B. Ferguson Unverified
10 segments
Speaker 88
1 segment
Representative Grant Hodges Unverified
2 segments
Representative DeAnn Vaught Unverified
2 segments
Speaker 117
23 segments
Speaker 80
1 segment
Representative Robin Lundstrum Unverified
2 segments
Representative Les Warren Unverified
5 segments
Representative Marcus E. Richmond Unverified
1 segment
Representative Mark Lowery Unverified
1 segment
Representative Tim Lemons Unverified
5 segments
Speaker 154
1 segment